biostudies-literatureUnknown17(9)Chen H<h4>Background</h4>San-Feng-Tong-Qiao-Di-Wan (SFTQDW) is a patented compound Chinese medicine used for acute and chronic rhinitis with few side effects. Its key components have antiallergic activity, making it potentially suitable for allergic rhinitis (AR). However, there is a lack of systematic research on its efficacy and mechanism of action for AR. This study aims to evaluate the potential and mechanism of SFTQDW in treating AR using network pharmacology, AR animal models, clinical observation, and serum metabolomics.<h4>Methods</h4>Network pharmacology was used to screen active ingredients and targets, followed by an AR mouse model study comparing SFTQDW 3.00 <i>vs.</i> 1.45 mg/g body weight <i>vs.</i> control. In a clinical substudy nested within an active-controlled trial, 35 AR patJournal of thoracic disease7155-7166https://www.ebi.ac.uk/biostudies/studies/S-EPMC12557684biostudies-literatureIntervention of traditional Chinese medicine San-Feng-Tong-Qiao-Di-Wan on allergic rhinitis: a network pharmacology and metabolomics study.PMC12557684Luo JChen HDeng XYan GPeng JXu YfalseIntervention of traditional Chinese medicine San-Feng-Tong-Qiao-Di-Wan on allergic rhinitis: a network pharmacology and metabolomics study.<h4>Background</h4>San-Feng-Tong-Qiao-Di-Wan (SFTQDW) is a patented compound Chinese medicine used for acute and chronic rhinitis with few side effects. Its key components have antiallergic activity, making it potentially suitable for allergic rhinitis (AR). However, there is a lack of systematic research on its efficacy and mechanism of action for AR. This study aims to evaluate the potential and mechanism of SFTQDW in treating AR using network pharmacology, AR animal models, clinical observation, and serum metabolomics.<h4>Methods</h4>Network pharmacology was used to screen active ingredients and targets, followed by an AR mouse model study comparing SFTQDW 3.00 <i>vs.</i> 1.45 mg/g body weight <i>vs.</i> control. In a clinical substudy nested within an active-controlled trial, 35 AR pat2025-01-01T00:00:00Z2025 Sep2026-06-05T07:19:22.712Z2026-05-14T03:08:58.022ZS-EPMC125576844115837610.21037/jtd-2025-1283